Middle East & Africa Regenerative Medicine Market Size & Outlook
Middle East & Africa regenerative medicine market, 2018-2030 (US$M)
Related Markets
MEA regenerative medicine market highlights
- The MEA regenerative medicine market generated a revenue of USD 360.0 million in 2023.
- The market is expected to grow at a CAGR of 10.5% from 2024 to 2030.
- In terms of segment, therapeutics was the largest revenue generating product in 2023.
- Banks is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 360.0 million |
| Market revenue in 2030 | USD 723.7 million |
| Growth rate | 10.5% (CAGR from 2023 to 2030) |
| Largest segment | Therapeutics |
| Fastest growing segment | Banks |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Therapeutics, Tools, Banks, Services |
| Key market players worldwide | AstraZeneca PLC, Roche Holding AG, Integra Lifesciences Holdings Corp, Astellas Pharma Inc, Cook Group, Bayer AG, Pfizer Inc, Merck KGaA, Abbott Laboratories, Vericel Corp, Novartis AG ADR, GlaxoSmithKline |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.2% of the global regenerative medicine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Europe is the fastest growing regional market and is projected to reach USD 27,062.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Regenerative Medicine Market Scope
Regenerative Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa regenerative medicine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to regenerative medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 76.78% in 2023. Horizon Databook has segmented the Middle East & Africa regenerative medicine market based on therapeutics, tools, banks, services covering the revenue growth of each sub-segment from 2018 to 2030.
Middle Eastern countries in the MEA face several challenges, such as complexity and lack of standardization in the regulation of licenses & recruitment. Investment by the private sector is low; more than 75% of the healthcare spending in these countries is by the government. However, the rising incidence of lifestyle-related diseases and increasing demand for standard healthcare provisions are expected to create demand for better healthcare solutions.
This is expected to contribute to revenue generation. Government efforts to encourage foreign investment, along with gradual improvement in the regulatory environment, are anticipated to contribute to the growth of its life sciences sector. Gradual progress in healthcare, pharmaceutical, and life sciences industries is expected to support market growth in the coming years.
Reasons to subscribe to Middle East & Africa regenerative medicine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa regenerative medicine market databook
-
Our clientele includes a mix of regenerative medicine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa regenerative medicine market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa regenerative medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA regenerative medicine market size, by country, 2018-2030 (US$M)
Middle East & Africa Regenerative Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
